

Currently Recruiting Clinical Trials for Patients with Advanced Uveal Melanoma

Clinical Trial Number	Title	Phase	Sites
NCT04728633	Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases	II	Sidney Kimmel Cancer Center at Thomas Jefferson University (Philadelphia, PA) <i>not yet recruiting</i> Carin Gonsalves, MD; 215-955-6385; Carin.Gonsalves@jefferson.edu
NCT01587352	Vorinostat in Treating Patients With Metastatic Melanoma of the Eye	II	Memorial Sloan Kettering Cancer Center (New York, NY) <i>recruiting</i> Alexander Shoushtari; 212-639-7592 Vanderbilt University/Ingram Cancer Center (Nashville, TN) <i>recruiting</i> Kristin Ancell; 800-811-8480
NCT03472586	Ipilimumab and Nivolumab with Immunoembolization in Treating Patients with Metastatic Uveal Melanoma in the Liver	II	Sidney Kimmel Cancer Center at Thomas Jefferson University (Philadelphia, PA) <i>recruiting</i> Marlana Orloff, MD; 215-955-8874; mmo@jefferson.edu
NCT03467516	Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma	II	UPMC Hillman Cancer Center (Pittsburgh, PA) <i>recruiting</i> Udai Kammula, MD Contact: Amy Rose, BSN; 412-647-8587; kennaj@upmc.edu Contact: Samantha Perkins, PA-C; 412-623-5960; perkinssj@upmc.edu
NCT03207347	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	II	Contact for all Sites: Alexandra Mueller; (352) 273-9785; PMO@cancer.ufl.edu University of Florida (Gainesville, FL) <i>recruiting</i> Thomas George, MD, FACP Contact: Nghi Lam; 352-265-5329; nghi.lam@cancer.ufl.edu University of Miami (Miami, FL) <i>recruiting</i> Peter J Hosein, MD Contact: Carla Montoya; ccm162@miami.edu Orlando Health UF Health Cancer Center (Orlando, FL) <i>not yet recruiting</i> Thomas Sajeve, MD Contact: Marie Frankos; marie.frankos@orlandohealth.com

This is an active clinical trial list retrieved from www.clinicaltrials.gov on August 17, 2021 and only includes sites in the United States. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

<u>NCT02519322</u>	Neoadjuvant and Adjuvant Checkpoint Blockade	II	<p>Memorial Sloan Kettering Cancer Center (New York, NY) <i>recruiting</i> Contact: Olivia Gibson, BS; 646-888-4365; gibsono1@mskcc.org</p> <p>MD Anderson Cancer Center Rodabe Amaria; 713-792-2921; rnamaria@mdanderson.org</p>
<u>NCT03947385</u>	Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions	I/II	<p>Contact for all Sites: <i>all sites recruiting</i> IDEAYA Clinical Trials; 650 534 361; IDEAYAClinicalTrials@ideayabio.com</p> <p>UCLA Medical Center (Los Angeles, CA) Contact: Bartosz Chmielowski, MD; BChmielowski@mednet.ucla.edu</p> <p>Florida Cancer Specialist South (Fort Myers, FL) Contact: James Reeves, MD; 239-274-9930; jreeves@flcancer.com</p> <p>Florida Cancer Specialist North (Saint Petersburg, FL) Contact: Vijay Patel, MD; 727-895-1143; vpatel@flcancer.com</p> <p>Mosaic Life Care (Saint Joseph, MO) Contact: Rony Abou-Jawde, MD; 816-271-1301; rony.abou-jawde@mymlc.com</p> <p>Columbia University Medical Center - Herbert Irving Pavilion (New York, NY) Contact: Richard Carvajal, MD; 646-317-6330; rdc2150@cumc.columbia.edu</p> <p>Sidney Kimmel Cancer Center at Thomas Jefferson University (Philadelphia, PA) Contact: Sarah Melendez; Sarah.melendez@jefferson.edu Contact: Cynthia Y Perez, BS, CCRP; Cynthia.Perez@jefferson.edu</p> <p>The Sarah Cannon Research Institute/Tennessee Oncology (Nashville, TN) Contact: askSARAH; 844-482-4812</p> <p>The University of Texas MD Anderson Cancer Center (Houston, TX) Contact: Filip Janku, MD; 713-792-6161; FJanku@mdanderson.org</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on August 17, 2021 and only includes sites in the United States. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

NCT03297424	A Study of PLX2853 in Advanced Malignancies	I/II	<p>Contact for all Sites: <i>all sites recruiting</i> Paul Watkins; 510-647-4151; PWatkins@plexikon.com Kerry Inokuchi; 510-647-4148; kinokuchi@plexikon.com</p> <p>Honor Health (Scottsdale, AZ) Contact: Leticia Aguilera; 623-238-7667; leaguilera@honorhealth.com</p> <p>Sylvester Comprehensive Cancer Center / University of Miami Miller School of Medicine (Miami, FL) Contact: Harshita Gahankari; 305-243-3379; harshita.gahankari@med.miami.edu</p> <p>Columbia University Medical Center (New York, NY) Contact: Elizabeth Vann; 212-305-3432; ev2480@cumc.columbia.edu</p> <p>South Texas Accelerated Research Therapeutics (START) (San Antonio, TX) Contact: Alex Amaya; alexamaya@startsa.com</p> <p>Virginia Cancer Specialists (Fairfax, VA) Contact: Alexander Spira, MD; Alexander.Spira@USOncology.com</p>
NCT03865212	Modified Virus VSV-IFNbeta-TYRP1 in Treating Patients with Stage III-IV Melanoma	I	<p>Mayo Clinic in Florida (Jacksonville, FL) <i>recruiting</i> Roxana Dronca, MD Contact: Clinical Trials S. Referral Office; 855-776-0015; mayocliniccancerstudies@mayo.edu</p> <p>Mayo Clinic in Rochester (Rochester, MN) <i>recruiting</i> Matthew Block, MD Contact: Clinical Trials S. Referral Office; 855-776-0015; mayocliniccancerstudies@mayo.edu</p>
NCT02768766	Intermittent Selumetinib for Uveal Melanoma	I	<p>Contact for all Sites: <i>all sites recruiting</i> Research Nurse Navigator, RN; 212-342-5162; cancerclinicaltrials@cumc.columbia.edu Richard Carvajal, MD; 646-317-6354; Rcd2150@cumc.columbia.edu</p> <p>Columbia University Medical Center (New York, NY) Richard Carvajal, MD; rdc2150@cumc.columbia.edu</p> <p>Memorial Sloan Kettering Cancer Center (New York, NY) Alexander N Shoushtari, MD; 646-888-4161; shoushta@mskcc.org</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on August 17, 2021 and only includes sites in the United States. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

			<p>MD Anderson Cancer Center (Houston, TX) Sapna Patel, M.D; 713-792-2921; melanoma@mdanderson.org</p>
<u>NCT04109456</u>	IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma	I	<p>Contact for all Sites: <i>all sites recruiting</i> Eddie Xing, Dr.; 949-520-0786; eddie.xing@inxmed.com</p> <p>Sylvester Comprehensive Cancer Center (Miami, FL) Lynn Feun, Dr.; 305-243-4981; lfeun@miami.edu</p> <p>Massachusetts General Hospital (Boston, MA) Ryan Sullivan, MD; 617-724-4000; RSULLIVAN7@PARTNERS.ORG</p> <p>Dana-Farber Cancer Institute (Boston, MA) Rizwan Haq, PhD.; 617-632-5055; Rizwan_haq@dfci.harvard.edu</p> <p>Columbia University Medical Center (New York, NY) Rachard Carvajal, Dr.; rdc2150@cumc.columbia.edu</p> <p>MD Anderson (Houston, TX) Sapna Patel; 713-792-2921 melanoma@mdanderson.org</p>
<u>NCT00986661</u>	A Study to Assess PV-10 Chemoablation of Cancer of the Liver	I	<p>Contact for all Sites: <i>only recruiting site(s) listed</i> Eric Wachter, PhD; 865-769-4011 ext 23; wachter@pvct.com</p> <p>MD Anderson Cancer Center (Houston, TX) <i>recruiting</i> Sapna Patel, MD Contact: Krysta McVay, RN, OCN; 832-596-2693; kmcvay@mdanderson.org</p>
<u>NCT03635632</u>	C7R-GD2.CART Cells for Patients with Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)	I	<p>Baylor College of Medicine/ Texas Children's Hospital/ Houston Methodist Hospital (Houston, TX) <i>recruiting</i> Contact: Bilal Omer, MD; 832-824-6855; bomer@bcm.edu Contact: David Allen; 832-824-4391; dlallen@texaschildrens.org</p>
<u>NCT04429542</u>	Study of Safety and Tolerability of BCA101 Alone and in Combination with Pembrolizumab in Patients with EGFR-Driven Advanced Solid Tumors	I	<p>Contact for all Sites: <i>all sites recruiting</i> David Bohr, MS, MPH, MBA; 516-603-7631; david.bohr@bicara.com</p> <p>Dana Farber/Partners Cancer Care Inc (Boston, MA) Glen Hanna, MD Contact: Karly Griffin; 617-632-6287; Karly_Griffin@DFCI.HARVARD.EDU</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on August 17, 2021 and only includes sites in the United States. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

			<p>Memorial Sloan Kettering (New York, NY) Paul Paik, MD Contact: Robert C Dyson; 646-888-4202; DysonR@mskcc.org</p> <p>Columbia University Herbert Irving Comprehensive Cancer Center (New York, NY) Richard Carvajal, MD Contact: CPDM Nurse Navigator; 212-342-5162</p> <p>MD Anderson Cancer Center (Houston, TX) Filip Janku, MD Contact: Vanda Stepanek, MD PhD CCRP; 713-792-4964; vstepane@mdanderson.org</p>
<u>NCT02858869</u>	Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases	I	<p>Emory University/Winship Cancer Institute <i>recruiting</i> Mohammad Khan, MD, PhD; 404-778-3473; m.k.khan@emory.edu Contact: Giesla Rodgers; 404-778-5162; grogd01@emory.edu</p>
<u>NCT04589832</u>	Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma	I/II	<p>HealthPartners Institute Regions Cancer Care Center (Minneapolis, MN) <i>recruiting</i> Minneapolis, Minnesota Arkadiusz Z Dudek, MD, PhD; 651-254-3321; Arkadiusz.Z.Dudek@HealthPartners.Com Contact: Ahran Lee; 317-634-5842 ext 14; Alee@hoosiercancer.org</p>
<u>NCT04552223</u>	Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma	II	<p>University of Miami Sylvester Comprehensive Cancer Center (Miami, FL) <i>recruiting</i> Jose Lutzky, MD Contact: Christina C Estevez; 305-243-8376; cme101@med.miami.edu Contact: Ashley Kaufman; 305-243-1084; a.kaufman@med.miami.edu</p>
<u>NCT05004025</u>	Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma	I	<p>HonorHealth Research Institute (Scottsdale, AZ) <i>not yet recruiting</i> Justin Moser, MD; 480-323-1350; jmoser@honorhealth.com Contact: Joyce Schaffer, MSN, AOCNS; 480-323-1339 ext option #2; Joschaffer@HonorHealth.com</p>
<u>NCT04720417</u>	Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma	II	<p>Sidney Kimmel Cancer Center at Thomas Jefferson University (Philadelphia, PA) <i>recruiting</i> Takami Sato, MD, PhD; 215-955-8874; takami.sato@jefferson.edu</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on August 17, 2021 and only includes sites in the United States. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

NCT04935229	Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma	I	MD Anderson Cancer Center (Houston, Texas) <i>recruiting</i> Sapna Patel, MD Contact: Ginny Honaker, RN; 713-962-7404; VLHonaker@mdanderson.org
NCT03068624	Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma	I	MD Anderson Cancer Center (Houston, TX) <i>recruiting</i> Sapna P. Patel; 713-792-2921; melanoma@mdanderson.org
NCT04879017	FHD-286 in Subjects With Metastatic Uveal Melanoma	I	Contact for all Sites: Sarah Reilly, MD; 888-615-1298; sreilly@foghornrx.com Caroline Almon; 888-615-1298; calmon@foghornrx.com The Angeles Clinic and Research Institute (Los Angeles, CA) <i>recruiting</i> Inder Mehmi, MD University of Miami Health System, Sylvester Comprehensive Cancer Center (Miami, FL) <i>recruiting</i> Jose Lutzky, MD Massachusetts General Hospital (Boston, MA) <i>not yet recruiting</i> Kamaneh Montazeri, MD Dana Farber Cancer Institute (Boston, MA) <i>not yet recruiting</i> Elizabeth Buchbinder, MD Columbia University, Herbert Irving Comprehensive Cancer Center (New York, NY) <i>not yet recruiting</i> Richard Carvajal, MD Memorial Sloan Kettering Cancer Center (New York, NY) <i>not yet recruiting</i> Alexander Shoushtari, MD Sidney Kimmel Cancer Center - Jefferson Health (Philadelphia, PA) <i>not yet recruiting</i>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on August 17, 2021 and only includes sites in the United States. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

			<p>Marlana Orloff, MD</p> <p>Sarah Cannon Research Institute (Nashville, TN) <i>recruiting</i></p> <p>Meredith McKean, MD</p> <p>MD Anderson Cancer Center (Houston, TX) <i>recruiting</i></p> <p>Sapna Patel, MD</p>
<u>NCT03611868</u>	A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors	I/II	<p>Contact for all Sites: <i>all sites recruiting</i> Kathryn Shantz; 301-802-3414; kate.shantz@ascentage.com</p> <p>University of Arizona Cancer Center (Tucson, AZ) Montaser Shaheen, MD Contact: Jose Vasquez; jrv3@email.arizona.edu</p> <p>Highlands Oncology (Rogers, AR) Thad Beck, MD; 479-936-9900</p> <p>UCLA Hematology & Oncology Clinic (Los Angeles, CA) Bartosz Chemielowski, MD</p> <p>Children's National Research Institute (Washington, DC) AeRang Kim, MD, PhD</p> <p>Sarah Cannon/FCSRI (Fort Myers, FL) James Reeves, MD Contact: Patrice Cowan; pcowan@flcancer.com</p> <p>Washington University School of Medicine (Saint Louis, MO) Brian Van Tine, MD, PhD</p> <p>Memorial Sloan Kettering (New York, NY) Sujana Movva, MD</p> <p>Penn State Hershey Medical Center Cancer Institute (Hershey, PA) Joseph Drabick, MD</p> <p>Thomas Jefferson University Hospital (Philadelphia, PA) Marlana Orloff, MD Contact: Joshua Zigmont; Joshua.zigmont@jefferson.edu</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on August 17, 2021 and only includes sites in the United States. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.

			<p>Sarah Cannon Cancer Center (Nashville, TN) Meredith McKean, MD</p> <p>University of Texas MD Anderson Cancer Center (Houston, TX) Neeta Somaiah, MD Contact: Gracy Zacharian; gzachari@mdanderson.org</p> <p>Next Oncology (San Antonio, TX) Anthony Tolcher, MD</p> <p>Virginia Cancer Specialists (Fairfax, VA) Alexander Spira, MD</p>
<u>NCT04551352</u>	A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas	I	<p>Contact for all Sites: <i>all sites recruiting</i> www.roche.com/about_roche/roche_worldwide.htm; 888-662-6728 (U.S. Only)</p> <p>Dana Farber Cancer Institute (Boston, MA)</p> <p>Memorial Sloan-Kettering Cancer Center (New York, NY)</p> <p>Thomas Jefferson University Hospital;Medical Oncology (Philadelphia, PA)</p> <p>Sarah Cannon Research Institute (Nashville, TN)</p>
<u>NCT03635632</u>	C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)	I	<p>Contact for all Sites: <i>all sites recruiting</i> Bilal Omer, MD; 832-824-6855; bomer@bcm.edu David Allen; 832-824-4391; dlallen@texaschildrens.org</p> <p>Houston Methodist Hospital (Houston, TX) Bilal Omer, MD</p> <p>Texas Children's Hospital (Houston, TX) Bilal Omer, MD</p>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on August 17, 2021 and only includes sites in the United States. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.